A study of Ropivacaine heavy and Bupivacaine heavy in hypertensive patients undergoing surgery under spinal anaesthesia

Phase 4

Recruiting

• Conditions: Hypertensive heart and chronic kidney disease without heart failure, (2) ICD-10 Condition: I131||Hypertensive heart and chronic kidney disease without heart failure, (3) ICD-10 Condition: I119||Hypertensive heart disease withoutheart failure, (4) ICD-10 Condition: I119||Hypertensive heart disease withoutheart failure,

• Registration Number: CTRI/2022/06/043360
• Lead Sponsor: IGIMS

Brief Summary

we aimed to study the effectiveness of Ropivacine 0.75% and Bupivacaine 0.5% in patients with controlled hypertension undergoing surgery under spinal anaesthesia . The aim to study and evaluate the onset and duration of motor and sensory blockade of Ropivacaine 0.75% and Bupivacaine 0.5% and also the hemodynamic stability of patients and post operative analgesia.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2022-06-17
• Study Start: 2022-06-21

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

hypertensive patients, controlled blood pressure both male and female of age group 25- 70 years undergoing surgery under spinal anaesthesia .

Exclusion Criteria

• 1.Patient refusal for procedure.
• 2.ASA grade > III, IV 3.Emergency Surgery 4.Immunocompromised patients 5.All contraindications for Regional anaesthesia 1.
• Those with bleeding disorders and local sepsis.
• Those on anticoagulant and antiplatelet agent.
• Those allergic to amide anaesthetics.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Heart rate, Blood pressure, mean arterial pressure recordings	1min, 3min, 5min, 10min,15min,30min, 45min, 60 min intraoperative and postoperative period.

Secondary Outcome Measures

Name	Time	Method
modified bromage score for motor block assessment, global patient satisfaction scale, and patient comfort score	in the post operative period upto 3-4 hrs

Trial Locations

Locations (1)

IGIMS; 🇮🇳 Patna, BIHAR, India

IGIMS

🇮🇳Patna, BIHAR, India

Akrity Singh

Principal investigator

9431664293

drakrity_s@yahoo.co.in